

MEDTRONIC, INC.
REVENUE BY OPERATING SEGMENT
(Unaudited)

(\$ millions)

	FY 05 QTR 1	FY 05 QTR 2	FY 05 QTR 3	FY 05 QTR 4	FY 05 TOTAL	FY 06 QTR 1	FY 06 QTR 2	FY 06 QTR 3	FY 06 QTR 4	FY 06 TOTAL
REPORTED REVENUE :										
CARDIAC RHYTHM MANAGEMENT	\$ 1,097	\$ 1,104	\$ 1,150	\$ 1,265	\$ 4,616	\$ 1,268	\$ 1,289	\$ -	\$ -	\$ 2,557
Low Power Pacing	451	438	431	436	1,756	446	459	-	-	905
High Power Defibrillation	551	546	598	684	2,379	718	733	-	-	1,451
Emergency Response Systems	79	104	104	126	413	87	81	-	-	168
Other	16	16	17	19	68	17	16	-	-	33
SPINAL, ENT & NAVIGATION	\$ 484	\$ 506	\$ 536	\$ 599	\$ 2,125	\$ 589	\$ 603	\$ -	\$ -	\$ 1,192
Spinal Constructs	317	332	343	380	1,372	376	382	-	-	759
Spinal Biologics	89	99	107	118	413	128	134	-	-	261
Ear, Nose & Throat (ENT)	58	55	61	67	241	65	64	-	-	129
Navigation	20	20	25	34	99	20	23	-	-	43
NEUROLOGICAL and DIABETES	\$ 408	\$ 430	\$ 460	\$ 496	\$ 1,794	\$ 463	\$ 487	\$ -	\$ -	\$ 950
Neurological	170	179	184	206	739	186	204	-	-	389
Gastroenterology & Urology	42	45	49	52	188	49	48	-	-	97
Neurologic Technologies	50	53	56	59	218	55	57	-	-	112
Diabetes	146	153	171	179	649	173	178	-	-	352
VASCULAR	\$ 196	\$ 201	\$ 221	\$ 233	\$ 851	\$ 205	\$ 225	\$ -	\$ -	\$ 430
Stents	71	78	86	82	317	65	90	-	-	155
Other Coronary	71	71	77	89	308	81	78	-	-	160
Endovascular/Peripheral	54	52	58	62	226	59	57	-	-	115
CARDIAC SURGERY	\$ 161	\$ 159	\$ 164	\$ 185	\$ 669	\$ 165	\$ 161	\$ -	\$ -	\$ 327
Heart Valves	56	54	56	64	230	58	56	-	-	114
Perfusion	79	79	80	89	327	79	78	-	-	157
Cardiac Surgery Technologies	26	26	28	32	112	28	27	-	-	56
TOTAL	\$ 2,346	\$ 2,400	\$ 2,531	\$ 2,778	\$ 10,055	\$ 2,690	\$ 2,765	\$ -	\$ -	\$ 5,456
ADJUSTMENTS :										
CURRENCY (1)	35	40	59	32	\$ 166	26	(3)			\$ 23
COMPARABLE OPERATIONS (1)	\$ 2,311	\$ 2,360	\$ 2,472	\$ 2,746	\$ 9,889	\$ 2,664	\$ 2,768	\$ -	\$ -	\$ 5,433

(1) - Medtronic management believes that in order to properly understand Medtronic's short-term and long-term financial trends, investors may wish to consider the impact of foreign currency translation on revenue. In addition, Medtronic management uses results of operations before currency translation to evaluate the operational performance of the Company and as a basis for strategic planning. Investors should consider these non-GAAP measures in addition to, and not as a substitute for, financial performance measures prepared in accordance with GAAP.

Note: The data in this schedule has been intentionally rounded to the nearest million and therefore the quarterly revenues may not sum to the fiscal year to date revenues.